Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Hepatitis D, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Compensated Chronic Hepatitis B
Interventions: Drug: lamivudine; Drug: lamivudine; Drug: lamivudine, adefovir
Sponsors: Nanfang Hospital; Ministry of Health, China; GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [PEGASYS]; Drug: peginterferon alfa-2a [PEGASYS]; Drug: Adefovir
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Conditions: Cervical Neoplasia; HPV Infections
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Device: autoinjector; Device: pre-filled syringe
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified March 2010
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: ursodeoxycholic acid (UDCA) withdrawal and reinstitution
Sponsors: University of Tennessee; Mount Sinai School of Medicine; Children's Memorial Hospital; University of California, San Francisco; The Hospital for Sick Children; University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati; University of Pittsburgh
Not yet recruiting - verified March 2010
Condition: Hepatitis B Virus
Interventions: Drug: Peginterferon + Vitamin D; Drug: Peginterferon; Drug: Sebivo
Sponsor: Ziv Hospital
Not yet recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: ABT-072; Drug: Placebo
Sponsors: Abbott; Abbott Japan Co.,Ltd
Not yet recruiting - verified February 2010
Conditions: Liver Fibrosis; Liver Cirrhosis; Viral Hepatitis; Liver Tumour; Cardiac Failure; Biliary Cholestasis.
Interventions: Device: ARFI measurement; Device: ARFI measurement; Device: ARFI measurement
Sponsor: University Hospital, Bordeaux
Not yet recruiting - verified March 2010
Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified March 2010
Condition: Chronic Hepatitis C Virus Infection
Interventions: Drug: telaprevir; Drug: VX-222; Drug: ribavirin; Biological: peginterferon-alfa-2a; Drug: VX-222
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified March 2010
Condition: Hepatitis C Recurrence
Intervention: Drug: Nitazoxanide
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Condition: Hepatitis C, HCV, Chronic Hepatitis C, Hepatitis C Genotype 1
Interventions: Drug: ABT-450; Drug: ABT-072; Drug: ABT-333; Drug: ritonavir; Drug: pegIFN; Drug: ribavirin
Sponsor: Abbott
Not yet recruiting - verified February 2010
Condition: HCV Infection
Interventions: Drug: GS-9256; Drug: GS-9190; Drug: Ribavirin
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: Ad6NSmut; AdCh3NSmut; Biological: AdCh3NSmut; Ad6NSmut; Biological: AdCh3NSmut; Ad6NSmut
Sponsors: Okairos; University of Oxford
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Intervention:
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Bone Marrow; Bone Marrow Stromal Cells; Mesenchymal Stem Cells; Blood Donors
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2010
Condition: Immunocompromised
Intervention: Biological: Focetria (2x H1N1 vaccine with MF59 adjuvants)
Sponsor: Competence Network Viral Hepatitis
Recruiting - verified February 2010
Conditions: Hepatitis C, Chronic; Liver Diseases; Virus Diseases
Intervention:
Sponsor: University of Ulm
Recruiting - verified February 2010
Condition: Chronic Hepatitis B
Interventions: Drug: Entecavir; Drug: Tenofovir
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified March 2010
Condition: Hepatitis C Virus
Interventions: Drug: Ortho Tri-Cyclen®; Drug: BMS-650032
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified February 2010
Condition: HIV Infection
Intervention: Biological: blood test at day one
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: Ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Intervention: Drug: Telaprevir/standard treatment
Sponsors: Tibotec Pharmaceuticals, Ireland; Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified February 2010
Condition: Hepatitis C Virus Infection
Intervention: Drug: CTS-1027, Pegylated Interferon, Ribavirin
Sponsor: Conatus Pharmaceuticals Inc.
Recruiting - verified February 2010
Condition: Hepatitis C Infection
Interventions: Drug: BMS-790052; Drug: BMS-650032
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Hepatitis C Virus
Intervention: Drug: TMC435
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention:
Sponsor: Fundacion IMIM
Recruiting - verified November 2009
Condition: Hepatitis C, Chronic
Interventions: Drug: PEGASYS; Drug: COPEGUS
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Chronic Hepatitis B
Interventions: Drug: LB80380 90 mg; Drug: LB80380 150 mg; Drug: entecavir 0.5 mg
Sponsor: LG Life Sciences
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Hepatitis C Virus
Intervention: Drug: TMC435
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Conditions: Chronic Hepatitis C; Oxidative Stress
Interventions: Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)
Sponsors: The University of North Carolina, Chapel Hill; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health (NIH)
Recruiting - verified February 2010
Condition: Hepatitis C Infection
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: Peginterferon alfa-2a; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Hepatitis C Infection
Interventions: Drug: BMS-790052; Drug: BMS-790052; Drug: Placebo; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: BMS-650032; Drug: pegylated-interferon-α; Drug: ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Hepatitis C
Intervention: Drug: vaniprevir (MK7009)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: MK5172; Drug: Comparator: placebo
Sponsor: Merck
Not yet recruiting - verified February 2010
Condition: Hepatitis C
Interventions: Drug: Midazolam; Drug: BMS-791325
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Conditions: HIV Infections; Hepatitis C Virus
Interventions: Drug: Nitazoxanide (NTZ); Drug: Peginterferon alfa-2a (PEG-INF); Drug: Ribavirin (RBV)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2009
Conditions: Hepatitis C; Thrombocytopaenia
Intervention: Drug: Eltrombopag
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Filibuvir; Drug: Filibuvir; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Hepatitis C; HIV Infections
Interventions: Drug: telaprevir or matching placebo; Drug: telaprevir or matching placebo; Biological: peginterferon alfa-2a; Drug: ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-790052; Drug: Ortho Tri-Cyclen®
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Dyslipidemia
Interventions: Drug: anacetrapib; Drug: Comparator: atorvastatin; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Interventions: Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393; Drug: BMS-824393
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Chronic Hepatitis B
Intervention:
Sponsor: Chang Gung Memorial Hospital
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Hepatitis C
Intervention: Drug: Pegylated Interferons (Peg-IFN) and Ribavirin
Sponsors: University of Manitoba; Roche Pharma AG
Recruiting - verified February 2010
Condition: Chronic Hepatitis C Infection
Intervention: Drug: vaniprevir (MK7009)
Sponsor: Merck
Not yet recruiting - verified March 2010
Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Conditions: HIV Infections; Hepatitis C; HCV Infection
Interventions: Drug: PEG2b plus ribavirin followed by placebo; Drug: PEG2b plus ribavirin followed by boceprevir/PEG2b/ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: BMS-791325; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified November 2009
Condition: Chronic Hepatitis C Infection (HCV)
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (Peg-IFN); Drug: Comparator: Ribavirin (RBV)
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Hepatitis C; Pharmacokinetics
Interventions: Drug: BI 201335 NA; Drug: BI 201335 NA; Drug: BI 201335 NA; Drug: BI 201335 NA
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: Adefovir; Drug: Entecavir; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: entecavir; Drug: entecavir
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: HIV; HIV Infections
Interventions: Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line); Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line); Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; Gilead Sciences; Janssen Pharmaceutica N.V., Belgium
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention: Drug: filibuvir + Oral Contraceptives
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Hepatitis C
Intervention:
Sponsors: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited
Recruiting - verified March 2010
Conditions: Liver Fibrosis; Hepatitis C Virus
Intervention: Procedure: Comparator: Magnetic Resonance Elastography (MRE)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (peg-IFN) alfa-2a; Drug: Comparator: Ribavirin; Drug: Comparator: Placebo to vaniprevir
Sponsor: Merck
Not yet recruiting - verified March 2010
Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Hepatitis C
Interventions: Drug: vaniprevir; Drug: Pegylated Interferon; Drug: Ribavirin; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Hepatitis C, Chronic; Genotype 1; HCV-1
Interventions: Biological: Peginterferon alfa-2b; Drug: Ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Biological: Peginterferon alfa-2b; Drug: Ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Chronic Hepatitis C
Intervention: Procedure: Comparator: Fine needle aspiration biopsy
Sponsor: Merck
Recruiting - verified March 2010
Conditions: HIV Infections; Tuberculosis
Interventions: Drug: efavirenz; Drug: raltegravir; Drug: raltegravir
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; Gilead Sciences; Merck
Recruiting - verified February 2010
Conditions: Hepatitis C; Hepatitis C Virus
Interventions: Drug: Fluvastatin; Drug: Peginterferon alfa2a; Drug: ribavirin
Sponsor: University of Chicago
Recruiting - verified February 2010
Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: HIV; Hepatitis C
Interventions: Behavioral: Motivational interviewing; Behavioral: Educational intervention
Sponsors: Universitaire de Sherbrooke; Fonds de la Recherche en Santé du Québec
Recruiting - verified February 2010
Conditions: HIV Infection; HIV Seronegativity
Intervention:
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified March 2010
Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Liver Cancer; Hepatitis B; Hepatitis C
Intervention:
Sponsor: Stanford University
Recruiting - verified February 2010
Conditions: Liver Cancer; Hepatitis B; Hepatitis C
Intervention:
Sponsor: Stanford University
Recruiting - verified February 2010
Condition: Hepatitis B
Intervention: Other: Incentive condition
Sponsor: The National Centre in HIV Epidemiology and Clinical Research
Recruiting - verified February 2010
Conditions: Chronic Hepatitis C; Hepatitis C; HIV Infections
Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031) pen; Drug: Rebetol (ribavirin; SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Biological: Peginterferon alfa-2b; Drug: Ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis C, Chronic; Hepatitis C
Interventions: Biological: PegIntron (peginterferon alfa-2b; peginterferon α-2b; SCH 54031); Drug: Rebetol (ribavirin; SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Biological: Peginterferon alfa-2b; Drug: Ribavirin; Biological: Peginterferon alfa-2a; Drug: Ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis C, Chronic; Hepatitis C
Interventions: Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis C, Chronic; Hepatitis C
Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031; pegylated interferon alfa-2b); Drug: Rebetol (ribavirin; SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsor: Cangene Corporation
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: PF-00868554; Drug: PF-00868554; Drug: PF-00868554; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir; Drug: Adefovir Switching to Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Hepatitis C, Chronic
Interventions: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2009
Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: adefovir dipivoxil
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Chronic Hepatitis C; Atherosclerosis
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2009
Conditions: Hepatitis B; Hepatitis C
Intervention: Biological: blood sampling and abdominal sonography
Sponsor: National Taiwan University Hospital
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Treatment initiation for HIV-1 group O infected patients; Drug: Treatment initiation for HIV-1 group M infected patients
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting - verified February 2010
Conditions: HIV Infections; Tuberculosis
Interventions: Drug: rifabutin in combination with efavirenz; Drug: rifabutin in combination with nevirapine; Drug: rifabutin in combination with lopinavir/ritonavir
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: HIV Infections; Tuberculosis
Interventions: Drug: rifabutin in combination with efavirenz; Drug: rifabutin in combination with nevirapine; Drug: rifabutin in combination with lopinavir/ritonavir
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified February 2010
Conditions: Cholera; Diarrhea; Vibrio Infections
Interventions: Biological: Bivalent killed oral cholera vaccine; Biological: Killed Escherichia coli K12 placebo
Sponsors: International Vaccine Institute; Indian Council of Medical Research; National Institute of Cholera and Enteric Diseases, India; Shantha Biotechnics Limited
Recruiting - verified March 2010
Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Conditions: Schizophrenia; Cardiovascular Disease
Intervention:
Sponsors: Washington University School of Medicine; National Alliance for Research on Schizophrenia and Depression
Recruiting - verified March 2010
Condition: Hepatitis C
Intervention: Drug: Ribavirin
Sponsors: Maastricht University Medical Center; Roche Pharma AG
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: peginterferon alfa-2a [Pegasys]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention:
Sponsors: Rockefeller University; New York Presbyterian Hospital
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir; Drug: Tenofovir; Drug: Adefovir; Drug: Lamivudine
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Condition: Hepatitis B Infection
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: HIV
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2009
Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin; Drug: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Procedure: blood draw
Sponsor: Rockefeller University
Recruiting - verified March 2010
Conditions: Hepatitis C; Hepatitis C, Chronic
Interventions: Procedure: Continuous maintenance immunosuppressive therapy; Procedure: Immunosuppression withdrawal; Procedure: Liver transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified March 2010
Conditions: Hemoglobinopathies; Hemolysis; Iron Deficiency and Overload; Anemias
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Condition: Hepatitis C
Intervention:
Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2010
All Categories ... by Medical Condition » ... Hepatitus 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
